TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2864374
Drug: Beta-blocker (oxprenolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (oxprenolol) treatment
Study: 27664491
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day resveratrol capsules
Study: 29885904
Drug: Ziprasidone 20
Normalized name: ziprasidone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 20 mg
Study: 10536125
Drug: Oseltamivir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (75 mg once daily)
Study: 10536125
Drug: Oseltamivir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (75 mg twice daily)
Study: 2252170
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with propofol and alfentanil
Study: 2252170
Drug: Inhalation anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anaesthesia with nitrous oxide and enflurane at 1.3 MAC
Study: 25483647
Drug: Bivalent CYD
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent CYD vaccine against serotypes 1 and 3 (CYD-1;3) on day 0 and CYD-2;4 on day 105 (± 15 days)
Study: 25483647
Drug: Tetravalent blend
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent blend of CYD-1;3;4 and VERO cell derived, live attenuated vaccine against serotype 2 (VDV-2)
Study: 25483647
Drug: Japanese encephalitis
Normalized name: Japanese Encephalitis IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese encephalitis (JE) vaccine followed by CYD-TDV
Study: 25483647
Drug: Tetravalent CYD
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent CYD vaccine (CYD-TDV)
Study: 19236546
Drug: Combizym treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combizym treatment (2 weeks, two tablets post-meal, t.i.d.)
Study: 19236546
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (2 weeks, two tablets post-meal, t.i.d.)
Study: 15470286
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blockers (irbesartan, olmesartan medoxomil, telmisartan, valsartan) in combination with hydrochlorothiazide (40 mg/25 mg)
Study: 15470286
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blockers with hydrochlorothiazide
Study: 15470286
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with either angiotensin II receptor blockers or hydrochlorothiazide
Study: 11828263
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose dacarbazine (arm A)
Study: 11828263
Drug: High-dose dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose dacarbazine (arm B)
Study: 2105243
Drug: hMG +
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG + GH (24 IU on alternate days, total dose 144 IU)
Study: 548209
Drug: Lecithin administration
Normalized name: Lecithin
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecithin administration
Study: 31182060
Drug: Running therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Running therapy (exercise planned two times a week for 6 months)
Study: 31182060
Drug: Running therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Running therapy
Study: 16774872
Drug: Charcoal (CC)
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Charcoal (CC) filter tipped cigarettes
Study: 8901078
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg controlled-release (CR) oxycodone tablet
Study: 8901078
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg immediate-release (IR) oxycodone solution
Study: 1670668
Drug: Enzyme-linked immunosorbent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-linked immunosorbent assay (ELISA) for cerebrospinal fluid antibodies
Study: 1670668
Drug: Antibody ELISA
Normalized name: pseudopterogorgia elisabethae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody ELISA in controls
Study: 6666226
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ISDN (acute treatment)
Study: 6666226
Drug: 4 X
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 X 60 mg ISDN (4 weeks treatment)
Study: 22151932
Drug: 2% hydroquinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% hydroquinone cream
Study: 27345284
Drug: Isavuconazonium sulfate
Normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Isavuconazonium sulfate 744 mg (delivering 400 mg isavuconazole)
Study: 27345284
Drug: Isavuconazonium sulfate
Normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Isavuconazonium sulfate (oral administration)
Study: 27345284
Drug: Isavuconazonium sulfate
Normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Isavuconazonium sulfate 372 mg (delivering 200 mg isavuconazole) with esomeprazole 40 mg/day
Study: 24594863
Drug: Calcium/vitamin D
Normalized name: CALCIUM/VITAMIN D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium/vitamin D supplementation (1,000 mg of elemental calcium + 400 IU of vitamin D3 daily)
Study: 22648731
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g per day of cis9,trans11 CLA‐enriched oil
Study: 20079786
Drug: L-theanine (97
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine (97 mg) and caffeine (40 mg)
Study: 17639029
Drug: Linezolid (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (single and multiple dosing)
Study: 16343096
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) administration after metformin treatment (group A)
Study: 16343096
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) administration after laparoscopic ovarian drilling (LOD) (group B)
Study: 26152410
Drug: Oral afoxolaner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral afoxolaner chewable (NexGard) (dosage 3.1 - 6.2 mg/kg)
Study: 22727976
Drug: Nebivolol 5mg
Normalized name: NEBIVOLOL 5MG TAB
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebivolol 5mg daily (n=27)
Study: 20943711
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Pharmacotherapy + Physiotherapy)
Study: 19649309
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 to 300 mg/day)
Study: 19649309
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 to 20 mg/day)
Study: 15200753
Drug: Oxycodone/acetaminophen 10/650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/acetaminophen 10/650 mg (single dose)
Study: 15200753
Drug: Oxycodone/acetaminophen (multidose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/acetaminophen (multidose regimen)
Study: 15200753
Drug: Oxycodone/acetaminophen
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone/acetaminophen
Study: 15200753
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (Rofecoxib or Oxycodone/acetaminophen)
Study: 2915410
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl citrate (75 micrograms/h)
Study: 2915410
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl citrate
Study: 1069608
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of daunorubicin, cytosine arabinoside, 6-thioguanine, and pyrimethamine
Study: 31221165
Drug: Multi-arm trial
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-arm trial designs with varying antibiotic treatment durations
Study: 28094141
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg intravenous zanamivir
Study: 28094141
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg intravenous zanamivir
Study: 28094141
Drug: Oseltamivir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (75 mg oral, twice a day)
Study: 21525686
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 2% lidocaine HCl with 1:80,000 epinephrine injected into the buccal vestibule
Study: 17138173
Drug: Palatal injection
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatal injection
Study: 9101374
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (0.05 mg/day 17 beta‐estradiol) and calcium
Study: 9101374
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen in high bone turnover (HT) patients
Study: 9101374
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen in low bone turnover (LT) patients
Study: 1529687
Drug: Insulin‐like Growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐like Growth Factor I (IGF I) plasma levels in children with Perthes' disease
Study: 1529687
Drug: Insulin‐like Growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐like Growth Factor I (IGF I) plasma levels in matched controls
Study: 29099960
Drug: PNCA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNCA with a basal infusion
Study: 29099960
Drug: PNCA without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PNCA without a basal infusion
Study: 29099960
Drug: PNCA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNCA (both with and without basal infusion)
Study: 11583720
Drug: colesevelam 3.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: colesevelam 3.8 g/day
Study: 19508464
Drug: atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 10 mg/day
Study: 11583720
Drug: coadministered colesevelam
Approvals — FDA: no, EMA: no, PMDA: no
Description: coadministered colesevelam 3.8 g/day plus atorvastatin 10 mg/day
Study: 18809153
Drug: atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 80 mg/day
Study: 8018463
Drug: Nadroparin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (0.4 ml)
Study: 8018463
Drug: Enoxaparin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.4 ml)
Study: 31865604
Drug: 2 consecutive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 consecutive daily fractions of 5-6 Gy
Study: 24920349
Drug: Levosimendan (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.2 µg/kg/min) administered for 6 h at 2-week intervals over 6 weeks
Study: 24920349
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 6 h at 2-week intervals over 6 weeks
Study: 22746016
Drug: L group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L group (Landiolol)
Study: 16222918
Drug: Prenatal multiple
Normalized name: Ascorbic Acid/Biotin/Calcium/Cholecalciferol/Chromium/Copper/Cyanocobalamin/Docosahexaenoic Acid/Eicosapentaenoic Acid/Fish Oil/Folic Acid/Iodine/Iron/Magnesium/Manganese/Niacin/Pantothenic Acid/Phytonadione/Pyridoxine/Riboflavin/Selenium/Thiamine/Vitamin A/Vitamin E/Zinc 150 MG-150 MCG-50 MG-800 IU-60 MCG-1 MG-16 MCG-250 MG-50 MG-500 MG-400 MCG-75 MCG-13.5 MG-50 MG-1 MG-40 MG-20 MG-100 MCG-5 MG-4 MG-35 MCG-3.4 MG-4000 IU-75 IU-7.5 MG Oral Capsule, Liquid Filled [CARLSON PRENATAL MULTIPLE WITH DHA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal multiple micronutrient supplements (MM), 6 days per week from early pregnancy to delivery.
Study: 16222918
Drug: Iron only
Normalized name: Iron only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron only (FE) supplements, 6 days per week from early pregnancy to delivery.
Study: 16222918
Drug: Prenatal multiple
Normalized name: Ascorbic Acid/Biotin/Calcium/Cholecalciferol/Chromium/Copper/Cyanocobalamin/Docosahexaenoic Acid/Eicosapentaenoic Acid/Fish Oil/Folic Acid/Iodine/Iron/Magnesium/Manganese/Niacin/Pantothenic Acid/Phytonadione/Pyridoxine/Riboflavin/Selenium/Thiamine/Vitamin A/Vitamin E/Zinc 150 MG-150 MCG-50 MG-800 IU-60 MCG-1 MG-16 MCG-250 MG-50 MG-500 MG-400 MCG-75 MCG-13.5 MG-50 MG-1 MG-40 MG-20 MG-100 MCG-5 MG-4 MG-35 MCG-3.4 MG-4000 IU-75 IU-7.5 MG Oral Capsule, Liquid Filled [CARLSON PRENATAL MULTIPLE WITH DHA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal multiple micronutrient supplements (MM) among overweight women.
Study: 16222918
Drug: Iron only
Normalized name: Iron only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron only (FE) supplements among non-overweight women.
Study: 10510142
Drug: Chlorpromazine 50
Normalized name: chlorpromazine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine 50 mg
Study: 10831016
Drug: Risperidone 2
Normalized name: risperidone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 2 mg
Study: 8595789
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiagabine (TGB) hydrochloride monotherapy
Study: 8595789
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiagabine (TGB) hydrochloride monotherapy (high-dose)
Study: 1720407
Drug: Preinduction regimen
Normalized name: Anacin Aspirin Regimen Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preinduction regimen with low-dose methotrexate followed by CHOP-Bleo chemotherapy
Study: 1720407
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy with CHOP-Bleo
Study: 31408870
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (Sufi music at low tempo)
Study: 16825847
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no music therapy)
Study: 25539931
Drug: Midluteal (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midluteal (ML) phase after total sleep deprivation (TSD)
Study: 24166760
Drug: MC4‐NN2‐0453 (0.03-1.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC4‐NN2‐0453 (0.03-1.50 mg/kg single dose)
Study: 24166760
Drug: MC4‐NN2‐0453 (0.75-3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC4‐NN2‐0453 (0.75-3.0 mg/day multiple doses)
Study: 12140141
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m² intravenous bolus on days 1 and 8 plus cisplatin 100 mg/m² on day 1 every 4 weeks (VC)
Study: 12140141
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C 8 mg/m² i.v. on day 1, vindesine 3 mg/m² i.v. on days 1, 8, 15 and 22, plus cisplatin 100 mg/m² on day 1 every 4 weeks (MVP)
Study: 7796569
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 600 mg for 1 year
Study: 2082305
Drug: ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac tromethamine 10 mg 4 times a day as needed
Study: 2082305
Drug: aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 650 mg 4 times a day as needed
Study: 17473118
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of ACP-103 (20-300 mg)
Study: 17473118
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of ACP-103 (50-150 mg)
Study: 17473118
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of ACP-103 (up to 300 mg)
Study: 17473118
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of ACP-103 (up to 100 mg once daily for 14 days)
Study: 8237845
Drug: Formula supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula supplemented with taurine (479 mumol/L)
Study: 31666076
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (including Revefenacin and Tiotropium)
Study: 8109937
Drug: Teicoplanin (T)
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (T) systemic prophylaxis - 800 mg in 100 ml saline as a 5-min infusion 2.5 h before surgery
Study: 8109937
Drug: Teicoplanin (T)
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (T) regional prophylaxis - 400 mg in 100 ml saline as a 5-min infusion immediately after tourniquet inflation
Study: 25070100
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg once daily for 6 days
Study: 25070100
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg once daily for 7 days
Study: 15867643
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline spray
Study: 15867643
Drug: 3.0% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0% saline spray
Study: 12532101
Drug: Omalizumab (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (at least 0.016 mg/kg/IgE [IU/mL], administered subcutaneously every 4 weeks)
Study: 9895077
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride 0.01% administered via IV regional anesthesia (IVRA)
Study: 8892538
Drug: Slosson Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slosson Oral Reading Test‐Revised
Study: 26743526
Drug: 200 μg selenium
Normalized name: SELENIUM 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg selenium supplements (n=30)
Study: 25140995
Drug: Methimazole treatment
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole treatment (30 mg daily for at least 1 month, followed by titration)
Study: 25140995
Drug: Methimazole treatment
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole treatment with L-thyroxine (30 mg daily for at least 1 month, followed by titration with L-thyroxine)
Study: 21809168
Drug: RLAI (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLAI (25-50 mg i.m. every 2 weeks)
Study: 12616822
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 150 mg kg‐1 bolus followed by continuous infusion of 12 mg kg‐1 h‐1
Study: 7934757
Drug: Physically active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physically active commuting to work (PACW) 1 h daily for 10 weeks
Study: 31666039
Drug: Vaccine reminder
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine reminder and tracker bracelets (two types of silicone bracelets)
Study: 16839780
Drug: Cortisol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (30 mg)
Study: 12736018
Drug: 22 mL
Normalized name: ethanol 0.722 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 mL of a 1% lidocaine solution injected into the neurovascular bundles, the genitourinary diaphragm, and between the rectal wall and prostate
Study: 12736018
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 2% intrarectal lidocaine jelly
Study: 11068978
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) plus routine care (RC)
Study: 8839196
Drug: Pamidronate 100
Normalized name: pamidronate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 100 mg
Study: 1451816
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low dose heparin and AT
Study: 30636672
Drug: Leech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leech therapy (4-7 leeches, single session)
Study: 30636672
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (4 weekly sessions, 1 hour each)
Study: 24329506
Drug: recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant growth hormone (rhGH) treatment for 2 years
Study: 21124039
Drug: Weekly irinotecan-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan-based therapy
Study: 21124039
Drug: Biweekly irinotecan-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly irinotecan-based therapy
Study: 24625508
Drug: First-line therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line therapy
Study: 16343039
Drug: Fenofibrate +
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate + 10 mg folate
Study: 16343039
Drug: Fluvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (80 mg)
Study: 10904122
Drug: Total Sleep
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Sleep Deprivation (TSD) + Light Therapy (150 or 2500 lux)
Study: 10904122
Drug: Ongoing Lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing Lithium Treatment